PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and their Future Perspectives
Source : https://www.eurekaselect.com/article/127987
Cardiovascular disorders (CVDs) are the leading cause of death worldwide and are accelerated via the low level of low-density lipoprotein-cholesterol (LDL-C). The proprotein convertase subtilis/kexin type9 (PCSK9), a vital regulator...
Relevance: This review plays a pivotal role for the researchers and scientists working on PCSK9 inhibitors to treat cardiovascular disorders.
Share
Effect of blood lipids and lipid-lowering therapies on osteoarthritis risk: A Mendelian randomization study
Source : https://www.frontiersin.org/articles/10.3389/fmed.2022.990569/full
BackgroundWe aimed to investigate the effects of blood lipids and lipid-lowering agents on osteoarthritis (OA) risk.Materials and methodsWe performed Mendelian randomization (MR) analyses to estimate the causal effect of blood...
Conclusions: The findings suggested that LDL-C increments have independent protective effects on both knee and hip OA. LDL-C-lowering effects of statins may increase the risk of knee OA.
Share
Safety of PCSK9 inhibitors
Source : https://www.sciencedirect.com/science/article/pii/S0753332222013464?via=ihub
PCSK9 inhibitors do not affect the increase in new cases of diabetes. * Treatment with PCSK9 inhibitors has a lower risk of muscle side effects. * PCSK9 inhibitors do not...
/>
Relevance: The purpose of this review is to summarize information on the safety profile of PCSK9 inhibitors, which may help in making therapeutic decision.
Share
Real-World Data on Comparison of Lipid-Lowering Effects between Alirocumab and Evolocumab in Patients with Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36440240/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The LDL-C lowering effects of alirocumab are similar to those of evolocumab in clinical practice.
Share
-
Lipid Management Connect3yrKey Points • Source: Acta Cardiologica Sinica • Conclusions: “The LDL-C lowering effects of alirocumab are similar to those of evolocumab in clinical practice.” • Taiwanese researchers compared characteristics, prescribed medications, plasma LDL-C levels, and percentages Show More
Statin intolerance management: a systematic review - Endocrine
Source : https://link.springer.com/article/10.1007/s12020-022-03263-w
Background Statin intolerance is a key barrier to the effective prevention of atherosclerotic cardiovascular disease (ASCVD). Experts do not agree on what it is and how to respond to this...
Conclusion: We found substantial variability in the definition and management of statin intolerance among experts. Few focused on ASCVD risk reduction and none promoted the participation of patients in shared decision making about how to address the threat of ASCVD with or without statins.
Share